Skip to content

Corpowell

Active
Private limited companyfounded 2020active for 6 yearsFrankrijklei 5, 2000 Antwerpen, Belgium229 active companies are registered at this addressKBO/BCE: BE 0742.572.315
Summary

The computed 12-month bankruptcy probability of Corpowell is 1.5% (moderate). The annual accounts of Corpowell for financial year 2025 show a net loss of 189% of the equity at the start of that year. The 2025 annual accounts show equity of €1.8m and a net result of -€506,242. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 59% of 9,797 sector peers (NACE 46, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
CorpowellActiveChecked score 56/100
Risk analysis ReportCompare

Directors

Directors
under verification, last change in 2025
This board is reconstructed from a single act (25353764). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.

Board 4

LIFESPAN
Director · since 23-07-2025 · Private limited company · permanent representative: VAN CAMPEN Anthony
Current
Seventure Partners
Director · since 23-07-2025 · Foreign entity · permanent representative: FREY DRAEGER NoraMaria
Current
TCI Biotech Netherlands
Director · since 23-07-2025 · Legal entity · permanent representative: LIN YungHsiang
Current
VAN CAMPEN Claire Nichola
Director · since 23-07-2025
Current

Permanent representatives 3

FREY DRAEGER NoraMaria
Permanent representative · since 23-07-2025 · for Seventure Partners
Current
LIN YungHsiang
Permanent representative · since 23-07-2025 · for TCI Biotech Netherlands
Current
VAN CAMPEN Anthony
Permanent representative · since 23-07-2025 · for LIFESPAN
Current

Statutory auditor 1

Finvision Bedrijfsrevisoren
Auditor · since 04-09-2025
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
2 of this company's 6 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.

Mandate history

6 people since 2025, 5 in office
Show
  • Board
  • Statutory auditor
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
LIFESPAN
  • Director, from 23-07-2025 to date
Seventure Partners
  • Director, from 23-07-2025 to date
TCI Biotech Netherlands
  • Director, from 23-07-2025 to date
VAN CAMPEN Claire Nichola
  • Director, from 23-07-2025 to date
Finvision Bedrijfsrevisoren
  • Auditor, from 04-09-2025 to date
VAN CAMPEN Anthony
  • Director, until 23-07-2025
See the board, name and registered office on a given date →

Owners and capital

Owners

1 owner

Chain of control

  1. LIFESPAN 57%
  2. Corpowell

Highest known parent: LIFESPAN. The sources do not say who stands above it.

Owners 1

Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Capital and shareholders

Shareholders according to the deeds
Stated in the act act of 17-04-2023 ↗
  • TCI BIOTECH Netherlands B.V. 167 shares

The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 04-09-2025 Capital increase of €1,300,000 · 1,300 new shares · in kind
  2. 04-09-2025 Capital increase of €2,000,000 · 2,000 new shares · in cash
  3. 17-04-2023 Capital increase of €150,000 · 167 new shares · in cash

We would like to set cookies. That happens only with your consent. What we measure